Meritxell V. C.
- Country
- Spain
- Department
- N/A
Research Overview
- Phase 2 Study of Empasiprubart in Deceased Donor Renal Allograft Recipients at Risk for Delayed Graft Function
- Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Efgartigimod Alfa SC in Antibody-Mediated Rejection in Kidney Transplant Recipients
- Efficacy and Safety of Imlifidase in Desensitizing Highly Sensitized End-Stage CKD Patients for Kidney Transplantation with Positive Crossmatch
Data & Insights
Has run more than one trial at 22 of 83 partner sites.
Specializations
Kidney Transplantation
This investigator specializes in living donor kidney transplantation with particular emphasis on developing personalized immunosuppressive approaches based on immunological risk assessment.
- Biomarker-based risk stratification
- Immunological monitoring
- Personalized immunosuppression
The research focus includes evaluating selective biomarkers for optimizing transplant outcomes.
Transplant Complications
The investigator studies critical complications in kidney transplantation, with specific attention to delayed graft function in deceased donor transplants and novel therapeutic interventions.
- Graft function optimization
- Novel therapeutic approaches
- Deceased donor outcomes
The work encompasses evaluation of innovative treatments for improving allograft function.
Transplant Rejection
A key area of investigation includes the management of antibody-mediated rejection in kidney transplant recipients, focusing on novel therapeutic agents and treatment approaches.
- Rejection management
- Innovative therapies
- Treatment safety evaluation
The research explores new therapeutic options for transplant rejection treatment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.